Literature DB >> 19381686

Association of hormone receptor status with grading, age of onset, and tumor size in BRCA1-associated breast cancer.

M Graeser1, K Bosse, M Brosig, C Engel, R K Schmutzler.   

Abstract

BRCA1-associated breast cancer frequently presents with estrogen-receptor (ERalpha) and progesterone-receptor (PR) negativity, grade 3, and early onset. In contrast, in BRCA1-deficient mice, ERalpha is highly expressed in early tumorigenesis. In a retrospective cohort study on 587 breast cancer patients with deleterious BRCA1 mutations, the correlation of ER, PR status, grading, age of onset, and tumor size was investigated. ERalpha and PR expression decreased from 62% in ductal carcinoma in situ (DCIS) to 20% and 16% in pT3, respectively (p value for ER 0.025 and PR 0.035, Fisher's exact test). The percentage of grade 1/2 tumors decreased from 44% in DCIS to 17% in pT3 (p value 0.074). Moreover, ER/PR positivity increased with increasing age. Our data suggest that early stage BRCA1-associated breast cancers are more frequently ERalpha and PR positive and low grade than advanced stages.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19381686     DOI: 10.1007/s00428-009-0760-8

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  25 in total

1.  Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes.

Authors:  F Eisinger; J Jacquemier; C Noguès; D Birnbaum; H Sobol
Journal:  Cancer       Date:  1999-05-15       Impact factor: 6.860

2.  Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.

Authors:  A Meindl
Journal:  Int J Cancer       Date:  2002-02-01       Impact factor: 7.396

3.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

4.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

Authors:  Noah D Kauff; Jaya M Satagopan; Mark E Robson; Lauren Scheuer; Martee Hensley; Clifford A Hudis; Nathan A Ellis; Jeff Boyd; Patrick I Borgen; Richard R Barakat; Larry Norton; Mercedes Castiel; Khedoudja Nafa; Kenneth Offit
Journal:  N Engl J Med       Date:  2002-05-20       Impact factor: 91.245

5.  Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS).

Authors:  W Remmele; K H Schicketanz
Journal:  Pathol Res Pract       Date:  1993-09       Impact factor: 3.250

6.  Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.

Authors:  Kelly Metcalfe; Henry T Lynch; Parviz Ghadirian; Nadine Tung; Ivo Olivotto; Ellen Warner; Olufunmilayo I Olopade; Andrea Eisen; Barbara Weber; Jane McLennan; Ping Sun; William D Foulkes; Steven A Narod
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

7.  Increased progesterone receptor expression in benign epithelium of BRCA1-related breast cancers.

Authors:  Tari A King; Mary L Gemignani; Weiwei Li; Dilip D Giri; Kathy S Panageas; Faina Bogomolniy; Crispinita Arroyo; Narciso Olvera; Mark E Robson; Kenneth Offit; Patrick I Borgen; Jeff Boyd
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

8.  Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.

Authors:  William D Foulkes; Kelly Metcalfe; Ping Sun; Wedad M Hanna; Henry T Lynch; Parviz Ghadirian; Nadine Tung; Olufunmilayo I Olopade; Barbara L Weber; Jane McLennan; Ivo A Olivotto; Louis R Bégin; Steven A Narod
Journal:  Clin Cancer Res       Date:  2004-03-15       Impact factor: 12.531

Review 9.  Hallmarks of 'BRCAness' in sporadic cancers.

Authors:  Nicholas Turner; Andrew Tutt; Alan Ashworth
Journal:  Nat Rev Cancer       Date:  2004-10       Impact factor: 60.716

10.  Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer.

Authors:  Laundette P Jones; Minglin Li; Ewa D Halama; Yongxian Ma; Ronald Lubet; Clinton J Grubbs; Chu-Xia Deng; Eliot M Rosen; Priscilla A Furth
Journal:  Oncogene       Date:  2005-05-19       Impact factor: 8.756

View more
  1 in total

1.  Immunophenotypic predictive profiling of BRCA1-associated breast cancer.

Authors:  Pawel Domagala; Tomasz Huzarski; Jan Lubinski; Karol Gugala; Wenancjusz Domagala
Journal:  Virchows Arch       Date:  2010-10-13       Impact factor: 4.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.